Metastatic Castration-Resistant Prostatic Cancer Clinical Trial
Official title:
A Phase II, Randomized, Multi-center Study of Cabazitaxel Versus Abiraterone or Enzalutamide in Poor Prognosis-metastatic Castration-resistant Prostate Cancer
The purpose of this study is to assess and compare the clinical benefit rate in patients with
metastatic castrate-resistant prostate cancer and poor prognostic factors treated with
cabazitaxel or novel hormonal agents (abiraterone or enzalutamide) as initial therapy, to
determine which treatment is most active in this population. Clinical benefit rate is defined
as PSA or measurable radiological response of any duration or stable disease for > or equal
to 12 weeks, in the absence of other indicators of progression.
There is option to cross-over onto the other arm if the patient progresses.
n/a